News Jazz pays $145m to resolve Xyrem antitrust disputes Jazz Pharma has offered to pay $145m to settle claims it paid to prevent generic versions of its narcolepsy drug Xyrem from reaching the US market.
News Novartis agrees $245m settlement over Exforge generics delay Novartis has said it will pay $245 million to resolve civil litigation in the US, which accuses it of a 'pay for delay' scheme involving generics of its high blood pressure therapy Exforge.
News EU authorities accuse Teva of breaking competition rules Teva accused of "pay for delay" deal with Cephalon.